Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T20:33:04.464Z.
Calculation as of: 2026-10-06T20:33:04.464Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 970d877bc7db717cbed859036c212f4e9de57f4ce891843b12d0c27006da4837
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Seaport Therapeutics, Inc. Common Stock
Market Cap
$929.83M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$934.79M
EV/Sales Ratio
11.51x
TTM Avg
10.07x
3Y Avg
9.06x
5Y Avg
9.06x
Market Cap
$921.06M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$914.73M
EV/Sales Ratio
2.75x
TTM Avg
2.28x
3Y Avg
2.71x
5Y Avg
2.71x
Market Cap
$952.91M
EV/Sales Ratio
N/A
TTM Avg
60100.68x
3Y Avg
43581.59x
5Y Avg
27036.85x
Market Cap
$953.81M
EV/Sales Ratio
87.73x
TTM Avg
120.79x
3Y Avg
120.79x
5Y Avg
120.79x
Market Cap
$887.99M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Seaport Therapeutics, Inc. Common Stock (SPTX) | $929.83M | N/A | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $934.79M | 11.51x | 10.07x | 9.06x | 9.06x |
| CeriBell, Inc. (CBLL)vs › | $923.53M | 8.95x | 7.82x | 8.63x | 8.63x |
| MoonLake Immunotherapeutics (MLTX)vs › | $921.06M | N/A | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $914.73M | 2.75x | 2.28x | 2.71x | 2.71x |
| Savara Inc. (SVRA)vs › | $952.91M | N/A | 60100.68x | 43581.59x | 27036.85x |
| Aktis Oncology, Inc. (AKTS)vs › | $953.81M | 87.73x | 120.79x | 120.79x | 120.79x |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $887.99M | N/A | N/A | N/A | N/A |
| Bioventus Inc. (BVS)vs › | $887.50M | 1.93x | 1.63x | 1.56x | 1.52x |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 1.58x | 1.77x | 2.17x | 3.33x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
